Search

Author/Creator Menzies, AM

1. L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients. (1st October 2020)

Authors:
Versluis, JM; Rozeman, EA; Menzies, AM; Reijers, ILM; Krijgsman, O; Hoefsmit, EP; van de Wiel, BA; Sikorska, K; Bierman, C; Dimitriadis, P; Gonzalez, M; Broeks, A; Kerkhoven, RM; Spillane, AJ; Haanen, JBAG; van Houdt, WJ; Saw, RPM; Eriksson, H; van Akkooi, ACJ; Scolyer, RA
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 2
Page Start:
A2
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study. (1st October 2020)

Authors:
Reijers, ILM; Rozeman, EA; Dimitriadis, P; Krijgsman, O; Bosch, LJW; Cornelissen, S; Bouwman, J; Versluis, JM; Rao, D; van de Wiel, B; Spillane, AJ; Scolyer, RA; Menzies, AM; van Akkooi, ACJ; Long, GV; Blank, CU
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 2
Page Start:
A15
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search